<DOC>
	<DOC>NCT01181427</DOC>
	<brief_summary>Study of ABT-267 in both healthy volunteers and Hepatitis C virus (HCV) genotype 1 infected subjects.</brief_summary>
	<brief_title>Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Cytochrome P-450 Enzyme Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Main Selection Criteria for Healthy Volunteers: Subject has provided written consent. Subject is in general good health. Females must be postmenopausal for at least 2 years or surgically sterile. Females must not be pregnant or breastfeeding. If male, subject is surgically sterile or practicing specific forms of birth control. Main Selection Criteria for HCV Genotype 1infected Volunteers: Subject has provided written consent. Subject has chronic HCV genotype 1 infection at screening. Liver biopsy within 3 years with histology. Females must be postmenopausal for at least 2 years or surgically sterile. Females must not be pregnant or breastfeeding. If male, subject is surgically sterile or practicing specific forms of birth control. Subject is in general good health, as perceived by the investigator, other than HCV infection. Main Selection Criteria for Volunteers in the Resistance Monitoring Portion of the Study: Subject has provided written consent, has received at least one dose of ABT267 or placebo in the study, and is considered suitable by the investigator to participate. Exclusion Criteria Main Exclusion Criteria for Healthy Volunteers: Positive test for HAV IgM, HBsAg, HCV Ab or HIV Ab. Clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder. Use of tobacco or nicotinecontaining products with the 6month period prior to study drug administration. Abnormal screening laboratory results. Significant sensitivity to any drug. Requirement for any over the counter and/or prescription medication, vitamins and/or herbal supplements on a regular basis. Main Exclusion Criteria for HCV Genotype 1infected Volunteers: Significant sensitivity to any drug. Positive HBsAg, HAVIgM, and HIV Ab. Use of CYP enzyme inducers or inhibitors within 1 month of dosing. Clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid disease (except hypothyroidism on stable thyroid replacement therapy), or any uncontrolled medical illness or psychiatric disorder. Use of any medications (prescription and overthe counter) within 2 weeks prior to study drug dosing without prior approval by the Abbott Medical Monitor. Use of any vitamins or herbal supplements within 2 weeks prior to study drug dosing. Prior treatment with any investigational or commercially available antiHCV agents. Abnormal screening laboratory results.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>